MONITOR ( DrugBank: MONITOR )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
| 11 | 重症筋無力症 | 1 |
| 81 | 先天性副腎皮質酵素欠損症 | 1 |
| 129 | 痙攣重積型（二相性）急性脳症 | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000002276 | 2009/08/01 | 01/08/2009 | Developmental research of communication devices based on the brain machine interface using electroencephalograms | Developmental research of communication devices based on the brain machine interface using electroencephalograms - Communication devices using EEG-based BMI | amyotrophic lateral sclerosis | Let the patients use the communication devices to select characters on a computer monitor as they intend by recording EEG. | Osaka University | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 10 | Not applicable | Japan |
11. 重症筋無力症
臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-OCC-14004533 | 2014-04-30 | 2014-04-16 | The superior anesthetic management scheme during perioperative period for myasthenia gravis patients | The superior anesthetic management scheme during perioperative period for myasthenia gravis patients | myasthenia gravis | volunteer:muscle relaxant monitor;MG group:muscle relaxant monitor; | Yijishan Hospital, Wannan Medical College, Wuhu 241001, China | NULL | Completed | 10 | 66 | Both | volunteer:30;MG group:30; | China |
81. 先天性副腎皮質酵素欠損症
臨床試験数 : 87 / 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2031210491 | 04/01/2022 | 17/12/2021 | Double-blind comparison of Chronocort versus standard hydrocortisonereplacement therapy in participants aged 16 years and over with congenital adrenalhyperplasia | A randomized, Double-Blind, Active-Controlled, Phase 3 Study ofChronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy inParticipants Aged 16 Years and Over with Congenital Adrenal Hyperplasia | Congenital adrenal hyperplasia (CAH) | Participants randomized to Chronocort will receive 10 mg Chronocort in the morning on waking (typically between 06:00 and 08:00), placebo in the afternoon (between 15:00 and 17:00) and 20 mg Chronocort at night just prior to going to bed (typically between 22:00 and midnight). A maximum of 3 dose reductions will be allowed, resulting in a minimum final dose of 15 mg a day. Participants randomized to immediate-release hydrocortisone (IRHC) will receive 20 mg IRHC in the morning on waking (typically between 06:00 and 08:00), 10 mg IRHC in the afternoon (between 15:00 and 17:00) and placebo at night just prior to going to bed (typically between 22:00 and midnight). A maximum of 3 dose reductions will be allowed, resulting in a minimum final dose of 15 mg a day. The dose for both groups will be adjusted by an Independent blinded physician based on the androgen levels and adrenal function at Weeks 4, 10, and 16. At Week 16 the dose will be fixed and should remain unchanged. The blinded titrator can complete a dose increase at week 32 of 5 mg based on androgen results and adrenal function. Additionally, if a participant shows persistent signs of under replacement the Investigator can request 1 dose reversion of 5 mg, this will be discussed and agreed by the medical monitor. | Fujii Katsuya | NULL | Recruiting | >= 16age old | Not applicable | Both | 15 | Phase 2 | US;France;Turkey;Japan |
129. 痙攣重積型（二相性）急性脳症
臨床試験数 : 1 / 薬物数 : 1 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000041484 | 2020/04/10 | 21/08/2020 | The Safety and synergetic/additive neuroprotective effect of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion | Synergetic/additive neuroprotection of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion - Synergetic/additive neuroprotection of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion | Acute encephalopathy with biphasic seizures and late reduced diffusion or suspected | RIPoC (4 cycles of inflation 5 mins and deflation 5 mins) applied on a lower extremity using a blood pressure monitor cuff with 200 mmHg. | Paediatrics, St Mary's Hospital | NULL | Recruiting | 1months-old | 192months-old | Male and Female | 14 | Phase 2 | Japan |